EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Laurent Peyrin-Biroulet  ¹     Bruce E. Sands  ²     William Sandborn  ³     Peter D.R. Higgins  ⁴     Fumihito Hirai  ⁵     Vipul Jairath  ⁶     Ruth Belin  ⁷     Yan Dong  ⁷     Elisa Gomez Valderas  ⁷     Debra Miller  ⁷     Vipin Arora  ⁷     April Naegeli  ⁷     Paul Pollack  ⁷     Jay Tuttle  ⁷     Toshifumi Hibi  ^8    
1 Nancy University Hospital Inserm U954, Vandoeuvre les Nancy, France
² Icahn School of Medicine at Mount Sinai, New York, United States
³ University of California San Diego, La Jolla, United States
⁴ University of Michigan Health System School of Public Health, Ann Arbor, United States
⁵ Fukuoka University Chikushi Hospital, Chikushino, Japan
⁶ University of Western Ontario, London, Canada
⁷ Eli Lilly and Company, Indianapolis, United States
⁸ Kitasato Institute Hospital IBD Research and Treatment, Tokyo, Japan

Session
IBD (Posters)

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)